Development of new therapeutic agents for endometriosis: inhibitors of nuclear factor-kappa B pathway
Project/Area Number |
15K10671
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Obstetrics and gynecology
|
Research Institution | Tottori University |
Principal Investigator |
|
Co-Investigator(Kenkyū-buntansha) |
谷口 文紀 鳥取大学, 医学部, 准教授 (40322218)
伊澤 正郎 鳥取大学, 医学部, 特任教授 (50032222)
|
Project Period (FY) |
2015-04-01 – 2018-03-31
|
Project Status |
Completed (Fiscal Year 2017)
|
Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2017: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2015: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
Keywords | 子宮内膜症 / NF-kB / IAP阻害薬 / NFκB / IAP / 子宮内膜症細胞 / 卵巣チョコレート嚢胞 / TAK1 |
Outline of Final Research Achievements |
Local inflammatory reaction in the peritoneal environment is one of the contributing factors in the pathogenesis of endometriosis. In women with endometriosis, the peritoneal fluid (PF) is remarkable for an increased number of activated macrophages and inflammatory factors. We demonstrated the presence of increased levels of pro-inflammatory cytokines, such as tumor necrosis factor (TNF) α, interleukin (IL)-6, and IL-8 in the PF of patients with endometriosis. The pro-inflammatory cytokines, including TNFα and IL-8 released by peritoneal macrophages and endometriotic stromal cells, are upregulated by NF-κB.
|
Report
(4 results)
Research Products
(22 results)
-
-
-
-
-
[Journal Article] Serum Vascular Endothelial Growth Factor-A as a Prognostic Biomarker for Epithelial Ovarian Cancer.2017
Author(s)
Komatsu H, Oishi T, Itamochi H, Shimada M, Sato S, Chikumi J, Sato S, Nonaka M, Sawada M, Wakahara M, Umekita Y, Harada T.
-
Journal Title
Int J Gynecol Cancer.
Volume: 27(7)
Pages: 1325-1332
Related Report
Peer Reviewed
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-